Drug intelligence / Profile preview

SL-GD001

Development stage: Preclinical
Lead developer: SLBio
Modality: Cell Therapies

Overview

SL-GD001 is an **allogeneic gamma delta T cell therapy** being developed by **SLBio** for **glioblastoma**. The program is part of the company's non-genetically modified gamma delta T-cell platform and is designed to mediate **MHC-independent recognition and killing of tumor cells** through engagement of **tumor-associated markers** that have not been publicly specified. Based on the available company pipeline information, SL-GD001 is a **preclinical** solid tumor immunotherapy program supported by in vitro and in vivo glioblastoma models.

Other names: allogeneic gamma delta T cell therapy for glioblastoma

Beyond the preview

Go deeper on SL-GD001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SL-GD001.

Explore the full profile